TerminatedEUCTR 2012-002954-21
An exploratory, blinded, randomized, placebo-controlled study in subjects with depressive disorder to investigate the effect of minocycline on relapse after successful intravenous ketamine/minocycl...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · Netherlands and 1 more location
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 80
- Sponsor
- Janssen-Cilag International N.V.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Belgium, Netherlands, Spain
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2012-002954-21
- Official title
Show the full official title
An exploratory, blinded, randomized, placebo-controlled study in subjects with depressive disorder to investigate the effect of minocycline on relapse after successful intravenous ketamine/minocycl...
Recruitment & locations
TerminatedBelgium · Netherlands · Spain
Registry details
Historical country statuses
- Belgium — Prematurely Ended
- Spain — Prematurely Ended
- Netherlands — Prematurely Ended
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International N.V.
Is this study still recruiting?
The historical registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepr...
A Phase 2 Clinical Trial of GH001 in Patients with Bipolarity type II and a Current Major Depressive Episode (GH001-BD-202)